Enterprise Value
565.3M
Cash
235.1M
Avg Qtr Burn
-13.65M
Short % of Float
15.92%
Insider Ownership
25.38%
Institutional Own.
78.67%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Phase 2/3 Data readout | ||
ARX517 Details Solid tumor/s, Cancer, Prostate cancer | Phase 1/2 Data readout |